ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "FK506"

  • 2019 American Transplant Congress

    Functional Characterization of Orthotopic Hind-Limb Transplants in Rats

    F. Zheng, X. Zhang, L. Qiu, J. Wang, X. Yeap, K. M. Koss, J. Wertheim, Z. J. Zhang

    Comprehensive Transplant Center and Department of Surgery, Northwestern University, Chicago, IL

    *Purpose: Vascularized composite allotransplantation (VCA) is a valid therapeutic option for patients with non-salvageable injuries such as severe burns or limb amputation. The immune response…
  • 2019 American Transplant Congress

    CYP3A5 Genotype Had No Influence on Renal Function after Renal Transplantation

    J. E. Kimpton, A. J. Hughes, I. MacPhee

    Renal Medicine and Transplantation, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom

    *Purpose: Tacrolimus metabolism rate has been reported to be associated with renal function after renal transplantation (Thölking et al., 2014); this study aimed to determine…
  • 2019 American Transplant Congress

    Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation

    K. Budde1, S. Bunnapradist2, S. Patel3, D. Stevens3, U. Meier-Kriesche3, B. Suwelack4

    1Charité University Medicine Berlin, Berlin, Germany, 2UCLA Medical Center, Los Angeles, CA, 3Veloxis Pharmaceuticals Inc, Cary, NC, 4University Hospital of Münster, Münster, Germany

    *Purpose: A prospective study demonstrated safe and efficacious use of LCPT in de novo kidney transplantation. This study aims to evaluate tacrolimus trough levels and…
  • 2019 American Transplant Congress

    Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations within Ninety Days of Renal Transplant

    S. Patel, K. Khalil, A. Lichvar, E. Benedetti, P. West-Thielke

    University of Illinois Hospital and Health Sciences System, Chicago, IL

    *Purpose: Optimizing tacrolimus (TAC) time within therapeutic range (TTR) has been shown to improve outcomes post-transplant. To date, there are no studies assessing differences in…
  • 2019 American Transplant Congress

    A Retrospective Observational Analysis of Tacrolimus Metabolism Rate: No Evidence for Impact on Renal Function

    A. J. Hughes, J. E. Kimpton, I. MacPhee

    Renal Medicine and Transplantation, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom

    *Purpose: A previous publication found that fast metabolisers of tacrolimus had inferior renal function compared to slow metabolisers in a Caucasian population (Thölking et al.,…
  • 2019 American Transplant Congress

    Impact of Tacrolimus Formulation on Tacrolimus Level Coefficient of Variations

    S. January1, T. Horwedel2, J. Hagopian1, C. Carthon1, A. Gharabagi3, R. Delos Santos4

    1Barnes-Jewish Hospital, Saint Louis, MO, 2Veloxis Pharmaceuticals, Inc., Cary, NC, 3Saint Louis College of Pharmacy, Saint Louis, MO, 4Washington University School of Medicine, Saint Louis, MO

    *Purpose: Increased coefficient of variation (CV) of tacrolimus (FK) levels, indicating high intra-patient FK level fluctuations, are associated with increased rejection, development of donor-specific antibodies,…
  • 2019 American Transplant Congress

    Is Bariatric Surgery Feasible in the Setting of Liver and Kidney Transplants?

    L. M. Potter, A. Saharia, C. Mobley, K. Lunsford, M. Hobeika, N. Tariq, H. Podder, A. O. Gaber, R. M. Ghobrial

    Liver Transplant and Hepatobiliary Surgery, The Houston Methodist Hospital, Houston, TX

    *Purpose: Bariatric surgery benefits obese patients by promoting weight loss, improving quality of life, and reducing morbidity and mortality rates. There is concern, however, that…
  • 2019 American Transplant Congress

    Eupatilin Ameliorates Tacrolimus Induced Nephrotoxicity via Inhibiting Apoptosis

    H. J. Jang, C. S. Park, M. Y. Oh

    Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of

    *Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…
  • 2019 American Transplant Congress

    Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.

    J. Arreola Guerra1, R. Reyes Acevedo2, A. Chew Wong1, F. Haro Alcalde1, L. Zuñiga Macias1, R. Delgadillo Castañeda2, R. Villafan3

    1Internal Medicine and Nephrology, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, 2Transplantation, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, 3Universidad Autonoma de Aguascalientes, Aguascalientes, Mexico

    *Purpose: Tacrolimus (TAC) is part of the immunosuppression scheme of more than 95% of patients after kidney transplantation in Mexico. Low TAC tacrolimus trough levels…
  • 2019 American Transplant Congress

    In Depth Look at Acute Rejections in LCP-Tacrolimus (LCPT; Envarsus XR) and Immediate-Release Tacrolimus (IR-Tac)-Treated De Novo Kidney Transplant Recipients

    A. Condon1, M. Mujtaba2, S. J. Patel3, D. R. Stevens3, U. Meier-Kriesche3

    1University of New Mexico Hospitals, Albuquerque, NM, 2University of Texas Medical Branch, Galveston, TX, 3Veloxis Pharmaceuticals Inc., Cary, NC

    *Purpose: A prospective, randomized controlled trial has shown comparable rates of biopsy-proven rejection (BPAR) between LCPT and IR-Tac treated renal transplant recipients. This analysis aims…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences